In this review, we provide sophisticated and up-to-date insight into the therapeutic efficacy and safety of each IL-1 inhibitor in the treatment of monogenic autoinflmammatory periodic fever syndromes on the level of observational, open-label, randomized blinded controlled and registry-based studies. This evidence concerns the gene IL1B and periodic fever syndrome.